Compounds Raise Kalydeco’s Efficacy, May Be Future Combo Therapy

Compounds Raise Kalydeco’s Efficacy, May Be Future Combo Therapy

283377

Compounds Raise Kalydeco’s Efficacy, May Be Future Combo Therapy

Researchers boosted the activity of the cystic fibrosis transmembrane regulator (CFTR), the faulty protein at the heart of cystic fibrosis (CF), by altering the levels of a molecule called cyclic AMP (cAMP). Their results suggest that cAMP might make an effective add-on therapy to approved CFTR modulators like Kalydeco (ivacaftor). The study, “Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells,” was published in the journal Nature Scientific Reports. Although cases of CF involve…

You must be logged in to read/download the full post.